RhumbLine Advisers’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

RhumbLine Advisers’s Portfolio YARW Stock Details YARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-54	Closed	-$332K	–	3111
2021 Q1	$332K	Buy	54 +4	+8%	+$29K	﹤0.01%	2668
2020 Q4	$286K	Buy	50 +9	+22%	+$56.6K	﹤0.01%	2689
2020 Q3	$243K	Buy	41 +1	+3%	+$5.83K	﹤0.01%	2611
2020 Q2	$248K	Buy	40 +27	+208%	+$183K	﹤0.01%	2668
2020 Q1	$128K	Buy	13 +7	+117%	+$110K	﹤0.01%	2722
2019 Q4	$95K	Hold	6	–	–	﹤0.01%	2876
2019 Q3	$91K	Buy	6 +1	+20%	+$16.1K	﹤0.01%	2901
2019 Q2	$109K	Buy	5 +2	+67%	+$49.5K	﹤0.01%	2917
2019 Q1	$96K	Hold	3	–	–	﹤0.01%	2864
2018 Q4	$48K	Buy	+3	New	+$67.2K	﹤0.01%	2946

Other funds holding YARW

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

RhumbLine Advisers's YARW Position: Q2 2021 in Review

RhumbLine Advisers sold out of Yarrow Bioscience, Inc. Common Stock (YARW) in Q2 2021, closing a stake of 54 shares — an estimated $332K sold.

RhumbLine Advisers first reported a position in YARW in Q4 2018 and held it in 10 quarters. The position peaked at $332K in Q1 2021. 63 funds tracked by Wall St. Rank hold YARW as of Q2 2021.

RhumbLine Advisers reported no remaining Yarrow Bioscience, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
RhumbLine Advisers sold 54 Yarrow Bioscience, Inc. Common Stock shares in Q2 2021, an estimated $332K.
RhumbLine Advisers first reported a position in Yarrow Bioscience, Inc. Common Stock in Q4 2018 and held it in 10 quarters.
RhumbLine Advisers's Yarrow Bioscience, Inc. Common Stock position peaked at $332K in Q1 2021.
63 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.